December 15, 2022
Before closing out their review on the management of multiple myeloma, panelists consider disparities in care and share how these barriers are being addressed.
December 15, 2022
A comprehensive review of novel therapy being investigated in the setting of relapsed/refractory multiple myeloma to expand the bispecific antibody and CAR T-cell therapy armamentarium.
December 08, 2022
Shared insight on key factors that determine the best selection of therapy in patients with relapsed/refractory multiple myeloma, with a focus on bispecific antibodies and CAR T-cell therapy.
December 08, 2022
After reviewing their third patient case, expert hematologist-oncologists highlight the treatment armamentarium for relapsed/refractory multiple myeloma.
December 01, 2022
Before closing out their module on transplant-ineligible newly diagnosed multiple myeloma, panelists reflect on best treatment practices in the setting of high-risk disease.
December 01, 2022
Practical perspectives on the optimal selection of therapy for transplant-ineligible NDMM, followed by considerations for duration of therapy and dosing.
November 24, 2022
Expert perspectives on cornerstone induction therapy regimens used in patients with transplant-ineligible newly diagnosed multiple myeloma.
November 24, 2022
Switching their attention to the transplant-ineligible setting of newly diagnosed multiple myeloma, panelists center discussion around their second patient case.
November 17, 2022
Expert hematologist-oncologists consider the role of maintenance and consolidation following the completion of transplant in patients with newly diagnosed multiple myeloma.
November 17, 2022
A brief review of the role of transplant in patients with newly diagnosed multiple myeloma and how it can be best coupled with systemic treatment.